Maxim Group analyst Jason McCarthy maintained a Buy rating on RenovoRx (RNXT – Research Report) yesterday and set a price target of $9.00. The company’s shares opened today at $4.31.
According to TipRanks, McCarthy is an analyst with an average return of -34.2% and a 17.79% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Therap, SELLAS Life Sciences Group, and Oncolytics Biotech.
Currently, the analyst consensus on RenovoRx is a Moderate Buy with an average price target of $9.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.00 and a one-year low of $1.50. Currently, RenovoRx has an average volume of 31.3K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RNXT in relation to earlier this year. Most recently, in November 2022, Marton Laurence, a Director at RNXT bought 25,438.00 shares for a total of $43,244.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.
Read More on RNXT:
